Skin and subcutaneous diseases account for 44.84 million DALYs globally in 2021, ranking seventh in disability burden.

Ruxolitinib 1.5% cream significantly reduces pruritus and lesion severity among adults with prurigo nodularis for up to 12 weeks of treatment.

Hoth Therapeutics has reported interim data from a trial of HT-001, a drug designed for treating pruritus associated with ...